Jill Feldman: To Be Told You’re Cured… Only to Find Out You Aren’t
Jill Feldman, Lung Cancer Patient and Advocate, and Co-Founder of EGFR Resisters, shared Oncology Brothers‘s post on X, adding:
“Another important complexity of Stage III NSCLC that matters to patients and families:
We often call Stage III ‘locally advanced’ or include it in ‘early stage’. But the recurrence rate tells a very different story.
I know firsthand what it feels like to be told you’re cured… only to find out you aren’t – the grief and fear that comes with it is something we don’t talk about enough.
Hope and reality are NOT mutually exclusive. When discussing Stage III, be honest about potential benefits and risks, clear about the uncertainty, and approach it with compassion.”
Quoting Oncology Brothers‘s post:
“Treatment Algorithm: This is the algorithm we have used during our discussion with Deepa Rangachari for Stage I-III non-small cell Lung Cancer.
- Resectable disease
- Role of NGS early on
- Stage III unresectable disease
Also on the ‘Oncology Brothers’ podcast.”
Proceed to the video attached to the post.
More posts featuring Jill Feldman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023